GLYCINE

Search structure


Trade Names:	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER GLYCINE 1.5% IN PLASTIC CONTAINER
Synonyms:	Aminoacetic acid FEMA NO. 3287 Glycine Glycocoll Glycolixir NSC-25936
Status:	Approved
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	B05CX03
UNII:	TE7660XO1C

Structure


InChI Key	DHMQDGOQFOQNFH-UHFFFAOYSA-N
Smile	NCC(=O)O
InChI	InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C2H5NO2
Molecular Weight	75.07
AlogP	-0.97
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	1.0
Polar Surface Area	63.32
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	5.0

Pharmacology

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Ion channel Ligand-gated ion channel Glycine receptor	94000-95499	-	-	-	-
Ion channel Ligand-gated ion channel Ionotropic glutamate receptor NMDA receptor	68-200	86-690	-	126-170	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC03 and SLC07 families of heteromeric amino acid transporters (HATs) SLC07 Cationic amino acid transporter/glycoprotein-associated family	-	-	-	-	33-33
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family	-	31600	-	-	49-70

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Schizophrenia	3	D012559	ClinicalTrials
Malnutrition	3	D044342	ClinicalTrials
Diarrhea	3	D003967	ClinicalTrials
Hypertension	2	D006973	ClinicalTrials
Obsessive-Compulsive Disorder	2	D009771	ClinicalTrials
Psychotic Disorders	2	D011618	ClinicalTrials
Bipolar Disorder	2	D001714	ClinicalTrials
Cystic Fibrosis	2	D003550	ClinicalTrials
Asthma	2	D001249	ClinicalTrials
Alzheimer Disease	0	D000544	ClinicalTrials
Severe Acute Respiratory Syndrome	0	D045169	ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Nervous system disorders	16.67
Metabolism and nutrition disorders	13.33
Eye disorders	12.22
Injury, poisoning and procedural complications	11.11
Cardiac disorders	8.89
Investigations	7.78
Renal and urinary disorders	6.67
General disorders and administration site conditions	5.56
Respiratory, thoracic and mediastinal disorders	5.56
Gastrointestinal disorders	4.44
Vascular disorders	4.44

Cross References

Resources	Reference
CAS NUMBER	56-40-6
ChEBI	57305
ChEMBL	CHEMBL773
DrugBank	DB00145
DrugCentral	1319
EPA CompTox	DTXSID9020667
FDA SRS	TE7660XO1C
Human Metabolome Database	HMDB0000123
Guide to Pharmacology	4084
KEGG	C00037
PDB	GLY
PharmGKB	PA449789
PubChem	750
SureChEMBL	SCHEMBL6163
ZINC	ZINC000004658552

CONTENTS